NSE: CIPLA | BSE: 500087

Slowing Down Stock

Download real time

1192.40 -3.50 (-0.29%)

New 52W Low today

3.2M NSE+BSE Volume

NSE 02 Apr, 2026 3:31 PM (IST)

96,320

Market Cap

High in industry

Beta 1Year

Very Low volatility

Cipla Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CIPLA, BSE:500087 Cipla Ltd.

Search Inside the pdf :

Cipla Ltd.

25 Jan 2026

1192.40

-0.29%

Cipla (HOLD): A clear HOLD as valuation reflects pessimism

Hold: Cipla Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Sales/EBITDA /PAT reported -5.5%/-27.9%/-45% below our estimates. Ex of one-time cost, PAT reported 23% below our estimates

Cipla Ltd. has an average target of 1627.00 from 9 brokers.

Cipla Ltd.

24 Jan 2026

1192.40

-0.29%

EBITDA/earnings decline YoY after 13 quarters

Neutral: Cipla Ltd.

Target

Motilal Oswal

CIPLA delivered an in-line revenue. However, it posted lower-than-expected EBITDA/PAT (21%/22% miss) for the quarter. After almost 13 quarters, CIPLA exhibited a YoY decline in EBITDA in 3QFY26.

Number of FII/FPI investors decreased from 1085 to 1052 in Dec 2025 qtr

Cipla Ltd.

23 Dec 2025

1192.40

-0.29%

CIPLA LTD

Hold: Cipla Ltd.

Recommendation Target

Geojit BNP Paribas

Cipla Ltd delivered a steady Q2FY26 performance, supported by strong branded generics in India and continued leadership in its US respiratory business (albuterol MDI). The company's strategic focus on high-growth therapies such as obesity and diabetes (exclusive launch of Tirzepatide Yurpeak in India) underpins its long-term growth potential. However, near-term challenges remain, including the anticipated revenue erosion from the Revlimid cliff, increased R&D intensity weighing on margins, and execution risk related to timely approvals, which could limit earnings visibility and margin recovery in the medium term, thereby warranting a more...

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

04 Nov 2025, 12:00AM

1192.40

-0.29%

Growth outlook intact despite near-term headwinds

Accumulate: Cipla Ltd.

Target

Deven Choksey

Cipla’s near-to-medium term outlook remains positive, underpinned by strong execution in domestic formulations and a visible ramp-up in complex generics and biosimilars in the U.S. market.

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

31 Oct 2025

1192.40

-0.29%

Cipla (CIPLA IN) Q2FY26 Result Update Higher R&D...

Accumulate: Cipla Ltd.

Recommendation Target

Prabhudas Lilladhar

Number of FII/FPI investors decreased from 1085 to 1052 in Dec 2025 qtr

Cipla Ltd.

31 Oct 2025

1192.40

-0.29%

Cipla (BUY): On track to achieve USD1bn sales in North America

Buy: Cipla Ltd.

Target

BOB Capital Markets Ltd.

North America sales were higher at USD 233 mn, driven by 22% market share in gAlbuterol and 22% in gLanreotide (can scale to 30%)

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

31 Oct 2025

1192.40

-0.29%

Result Update:Cipla

Buy: Cipla Ltd.

Axis Direct

We remain positive on the stock with a BUY rating and arrive at a TP of Rs 1,700/share.

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

31 Oct 2025

1192.40

-0.29%

Cipla Ltd.

Buy: Cipla Ltd.

Target

ICICI Direct

The revenues were largely in line except India which was impacted by lower acute respiratory sales. The management is confident of better performance from India in the ensuing quarters. FY26 is likely to be a year of some consolidation with the genericization of gRevlimid and flattish US sales as major launches are expected to pick up momentum in FY27. On the EBITDA margins front, the management is guiding a range of 22.7524% which is slightly below the H1 exit range, due to lower Lenalidomide sales and higher R&D. The future remains bright as the company expects critical launches such as gAdvair (respiratory) by H2FY26 and also has a...

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

08 Sep 2025

1192.40

-0.29%

Growth outlook intact despite near-term headwinds

Hold: Cipla Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by +0.9%/-5.2%, as we factor in lower revenue on account of ramp down of Revlimid portfolio and ongoing price erosion in the US market, higher depreciation and amortization expense, offset by higher other income.

Cipla has lost -21.12% in the last 3 Months

Cipla Ltd.

02 Sep 2025

1192.40

-0.29%

India, RoW biz to stay steady, US drug pipeline - the next trigger

Buy: Cipla Ltd.

Target

Sharekhan

Cipla has robust domestic and global product pipelines. US product pipeline to be healthy and will be key to driving growth from H2FY26E and contribute significantly from FY27E onwards.

Cipla Ltd. is trading below all available SMAs

Is Cipla Ltd. worth buying?

648 Votes:

Buy 75.77%

Sell 13.58%

Hold 10.65%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Neutral SEE REPORTS >

pdf